World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
102
Citations
71365
World Ranking
655
National Ranking
382

Medicine

D-Index
102
Citations
71381
World Ranking
7478
National Ranking
3910

Bruce L. Levine publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Bruce L. Levine sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 340 publications — 72nd percentile

72% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Bruce L. Levine D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Bruce L. Levine sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 102 D-Index — 87th percentile

87% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Bruce L. Levine is affiliated with the University of Pennsylvania in the United States. Their research primarily spans the field of Medicine, with a particular emphasis on Oncology, Molecular Biology, Immunology, Physiology, and Biomedical Engineering. These subfields reflect the scientific breadth under which their work is conducted.

The main focus of Levine's work lies in CAR-T cell therapy research, with a total of 120 publications related to this topic. Other significant topics of their research include Immune Cell Function and Interaction, Biomedical Ethics and Regulation, Viral Infectious Diseases and Gene Expression in Insects, CRISPR and Genetic Engineering, Virus-based Gene Therapy Research, and Immunotherapy and Immune Responses.

Levine has published a number of research papers, notably:

  • "CRISPR-engineered T cells in patients with refractory cancer," 2020, Science
  • "Decade-long leukaemia remissions with persistence of CD4+ CAR T cells," 2022, Nature
  • "T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy," 2024, Nature Medicine
  • "Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia," 2020, Journal of Clinical Oncology
  • "Unanswered questions following reports of secondary malignancies after CAR-T cell therapy," 2024, Nature Medicine

They frequently publish in the journal Cytotherapy, contributing 48 articles there, followed by publications in Blood, Nature Medicine, bioRxiv (Cold Spring Harbor Laboratory), and Blood Advances.

Among Levine's frequent co-authors are Carl H. June, J. Joseph Melenhorst, Rachele Ciccocioppo, Jaap Jan Boelens, and Miguel Forte, each having collaborated on multiple occasions. This network highlights a collaborative environment within the field of immunotherapy and related biomedical research.

Best Publications

  • Chimeric antigen receptor T cells for sustained remissions in leukemia.

    Shannon L. Maude;Noelle Frey;Pamela A. Shaw;Richard Aplenc

  • Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

    S. L. Maude;Theodore W Laetsch;J. Buechner;S. Rives

  • Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

    David L. Porter;Bruce L. Levine;Michael Kalos;Adam Bagg

  • Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

    Stephan A. Grupp;Michael Kalos;David Barrett;Richard Aplenc

  • T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

    Michael Kalos;Bruce L. Levine;David L. Porter;Sharyn Katz

  • Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas

    Stephen J. Schuster;Jakub Svoboda;Elise A. Chong;Sunita D. Nasta

  • Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

    David L. Porter;Wei-Ting Hwang;Noelle V. Frey;Simon F. Lacey

  • A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.

    Donald M. O’Rourke;MacLean P. Nasrallah;Arati Desai;Jan J. Melenhorst

  • Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

    Joseph A. Fraietta;Simon F. Lacey;Elena J. Orlando;Iulian Pruteanu-Malinici

  • Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.

    Pablo Tebas;David Stein;Winson W. Tang;Ian Frank

  • CRISPR-engineered T cells in patients with refractory cancer

    Edward A. Stadtmauer;Joseph A. Fraietta;Megan M. Davis;Adam D. Cohen

  • Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma

    Gerald P. Linette;Edward A. Stadtmauer;Marcela V. Maus;Aaron P. Rapoport

  • Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics.

    Claudio G. Brunstein;Jeffrey S. Miller;Qing Cao;David H. McKenna

  • Engineered T cells: the promise and challenges of cancer immunotherapy

    Andrew D. Fesnak;Carl H. June;Bruce L. Levine

  • Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T cell Therapy for Acute Lymphoblastic Leukemia

    David T. Teachey;David T. Teachey;Simon F. Lacey;Pamela A. Shaw;J. Joseph Melenhorst

  • Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies

    Gregory L. Beatty;Andrew R. Haas;Marcela V. Maus;Drew A. Torigian

  • NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma

    Aaron P Rapoport;Edward A Stadtmauer;Gwendolyn K Binder-Scholl;Olga Goloubeva

  • Use of chimeric antigen receptor-modified t cells to treat cancer

    Carl H. June;Bruce L. Levine;David L. Porter;Michael D. Kalos

  • Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells

    Joseph A. Fraietta;Christopher L. Nobles;Morgan A. Sammons;Morgan A. Sammons;Stefan Lundh

  • Global Manufacturing of CAR T Cell Therapy

    Bruce L. Levine;James Miskin;Keith Wonnacott;Christopher Keir

  • Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells

    John Scholler;Troy L. Brady;Gwendolyn Binder-Scholl;Wei-Ting Hwang

Frequent Co-Authors

Carl H. June
Carl H. June University of Pennsylvania
David L. Porter
David L. Porter University of Pennsylvania
Simon F. Lacey
Simon F. Lacey University of Pennsylvania
Stephan A. Grupp
Stephan A. Grupp Children's Hospital of Philadelphia
Michael Kalos
Michael Kalos Next Pillar Consulting
J. Joseph Melenhorst
J. Joseph Melenhorst University of Pennsylvania
Edward A. Stadtmauer
Edward A. Stadtmauer University of Pennsylvania
Michael C. Milone
Michael C. Milone University of Pennsylvania
David M. Barrett
David M. Barrett Children's Hospital of Philadelphia
James L. Riley
James L. Riley University of Pennsylvania

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in Immunology, exploring related healthcare degrees can open up diverse career opportunities. Many professionals in research, clinical, and healthcare settings often complement their immunology background with nursing credentials.

One popular option includes online RN programs for non nurses in Florida. These programs allow non-nursing graduates to fast-track their way into Registered Nurse roles, leveraging their existing scientific knowledge.

Accelerated pathways like accelerated nursing programs provide an efficient route for those holding bachelor’s degrees in other fields to gain nursing credentials quickly, offering a strong clinical foundation relevant to immunology careers.

For those seeking entry-level nursing qualifications, lpn programs easy to get into offer accessible options that serve as stepping stones toward advanced roles in healthcare and immunology research support.

Lastly, pursuing advanced practice roles through what is the easiest NP program can lead to specialized career tracks combining clinical expertise with immunological knowledge, ideal for those aiming to contribute directly to patient care and immunotherapy development.

Best Scientists Citing Bruce L. Levine

Trending Scientists

Recently Published Articles